3 results
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Primary (PART 1A ONLY):Dose escalation: To determine the safety, tolerability, and the recommended phase 2 dose (RP2D) of GSK3745417 alone administered intravenously to participants with selected advanced/recurrent solid tumors.Secondary: (PART 1A…
Primary objective:To estimate the efficacy of dostarlimab in participants with Stage II/III (locally advanced) dMMR/MSI-H rectal cancer that has not been previously treatedSecondary Objectives:- To further estimate the efficacy of dostarlimab in…